Want to see HK:8158 full AI Analyst Report?

China Regenerative Medicine International Limited (8158) Price & Analysis

0 Followers

8158 Stock Chart & Stats

HK$0.41

HK$0.00(0.00%)

At close: Jan 06 4:00 PM EST

HK$0.41

HK$0.00(0.00%)

Day’s Range― - ―

52-Week RangeHK$0.21 - HK$1.04

Previous CloseN/A

Volume500.00

Average Volume (3M)55.39K

Market Cap

HK$69.07M

Enterprise ValueHK$170.92

Total Cash (Recent Filing)HK$8.17M

Total Debt (Recent Filing)HK$51.31M

Price to Earnings (P/E)2.5

Beta-0.08

Next Earnings

Aug 07, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.09

Shares Outstanding304,252,470

10 Day Avg. Volume53,325

30 Day Avg. Volume55,386

Financial Highlights & Ratios

PEG Ratio0.08

Price to Book (P/B)2.39

Price to Sales (P/S)1.77

P/FCF Ratio31.74

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Improved Balance-sheet LeverageA material reduction in debt-to-equity to ~1.11x by 2025 indicates healthier capital structure and greater financial flexibility. Sustained lower leverage reduces refinancing risk, improves interest coverage prospects, and supports strategic investment or R&D without immediate need for equity dilution.

Recent Revenue Rebound With Strong MarginsA notable revenue uptick combined with high gross and net margins suggests the business can scale sales while preserving product-level economics. If durable, this supports reinvestment capacity and indicates competitive pricing or cost efficiencies that underpin sustainable cash generation over the medium term.

Ability To Generate Positive Free Cash FlowHistorical positive free cash flow shows the company can convert operations into cash in favourable periods, lowering reliance on external funding. Even with a drop in 2025, prior FCF demonstrates operational cash-generation potential that can support capex, working capital and deleveraging when stability returns.

Bears Say

Weak And Inconsistent Cash-flow ConversionSharp deterioration in cash conversion despite reported net income signals earnings quality issues and working-capital or non-cash distortions. Persistent weak cash-flow conversion increases funding risk, may force external financing, and undermines the durability of reported profitability across 2–6 months.

Negative Operating Profitability (EBIT)A negative EBIT margin means core operations may not sustainably cover operating costs even if net income looks positive after one-offs. Continued weak operating profitability erodes intrinsic business strength, limits reinvestment, and makes margins vulnerable to cost or pricing pressure over the medium term.

Highly Volatile Returns And Remaining LeverageExtremely volatile ROE and still-material leverage leave the company exposed to earnings shocks. If profitability softens, balance-sheet sensitivity increases, raising refinancing and solvency risks. Volatile returns also complicate forecasting and investor confidence in sustainable performance.

8158 FAQ

What was China Regenerative Medicine International Limited’s price range in the past 12 months?

China Regenerative Medicine International Limited lowest stock price was HK$0.21 and its highest was HK$1.04 in the past 12 months.

What is China Regenerative Medicine International Limited’s market cap?

China Regenerative Medicine International Limited’s market cap is HK$69.07M.

When is China Regenerative Medicine International Limited’s upcoming earnings report date?

China Regenerative Medicine International Limited’s upcoming earnings report date is Aug 07, 2026 which is today.

How were China Regenerative Medicine International Limited’s earnings last quarter?

China Regenerative Medicine International Limited released its earnings results on Mar 30, 2026. The company reported HK$0.075 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is China Regenerative Medicine International Limited overvalued?

According to Wall Street analysts China Regenerative Medicine International Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does China Regenerative Medicine International Limited pay dividends?

China Regenerative Medicine International Limited does not currently pay dividends.

What is China Regenerative Medicine International Limited’s EPS estimate?

China Regenerative Medicine International Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does China Regenerative Medicine International Limited have?

China Regenerative Medicine International Limited has 304,252,470 shares outstanding.

What happened to China Regenerative Medicine International Limited’s price movement after its last earnings report?

China Regenerative Medicine International Limited reported an EPS of HK$0.075 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -10.667%.

Which hedge fund is a major shareholder of China Regenerative Medicine International Limited?

Currently, no hedge funds are holding shares in HK:8158

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

China Regenerative Medicine International Limited

China Regenerative Medicine International Limited operates as an investment holding entity, focusing on the development and distribution of a diverse portfolio of healthcare products and associated services. The company provides extensive health management solutions, covering health condition assessments, detoxification programs, fostering internal bodily balance, nourishing vital organs, and enhancing the immune system. Additionally, its beauty offerings encompass non-surgical medical aesthetics, essential dermatological care, anti-aging skin remedies, hair revitalization, skin firming treatments, localized body contouring, and intimate restoration services. Established in 1995, the organization was previously known as China Bio-Med Regeneration Technology Limited until its rebranding to China Regenerative Medicine International Limited in March 2015. Its headquarters are situated in Tsim Sha Tsui, Hong Kong.